These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 32845588

  • 1. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
    Rich P, Goldblum O, Disch D, Lin CY, Merola JF, Elewski B.
    J Drugs Dermatol; 2020 Aug 01; 19(8):741-746. PubMed ID: 32845588
    [Abstract] [Full Text] [Related]

  • 2. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
    Dennehy EB, Zhang L, Amato D, Goldblum O, Rich P.
    J Drugs Dermatol; 2016 Aug 01; 15(8):958-61. PubMed ID: 27537996
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M.
    Am J Clin Dermatol; 2017 Apr 01; 18(2):273-280. PubMed ID: 28074446
    [Abstract] [Full Text] [Related]

  • 4. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 investigators.
    Lancet; 2015 Aug 08; 386(9993):541-51. PubMed ID: 26072109
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, Cameron GS, Osuntokun OO, Japanese Ixekizumab Study Group.
    J Dermatol; 2017 Apr 08; 44(4):355-362. PubMed ID: 27726163
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.
    Feldman SR, Foster SA, Zhu B, Burge R, Al Sawah S, Goldblum OM.
    J Drugs Dermatol; 2017 Dec 01; 16(12):1246-1252. PubMed ID: 29240860
    [Abstract] [Full Text] [Related]

  • 9. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P.
    J Eur Acad Dermatol Venereol; 2017 Mar 01; 31(3):477-482. PubMed ID: 27910156
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
    Paller AS, Seyger MMB, Magariños GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, Somani N, Garrelts A, Papp KA, IXORA-PEDS Investigators.
    JAMA Dermatol; 2022 May 01; 158(5):533-541. PubMed ID: 35416908
    [Abstract] [Full Text] [Related]

  • 12. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 01; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, Shrom D, Amato D, Okubo Y, Reich K.
    J Eur Acad Dermatol Venereol; 2017 Oct 01; 31(10):1686-1692. PubMed ID: 28322474
    [Abstract] [Full Text] [Related]

  • 14. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, Goldblum O, Dennehy EB, Kerr L, Sofen H.
    J Dermatolog Treat; 2017 Jun 01; 28(4):282-287. PubMed ID: 27759463
    [Abstract] [Full Text] [Related]

  • 15. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J, IXORA-R Study Group.
    Br J Dermatol; 2020 Jun 01; 182(6):1348-1358. PubMed ID: 31887225
    [Abstract] [Full Text] [Related]

  • 16. Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis.
    Chigutsa E, Velez de Mendizabal N, Chua L, Heathman M, Friedrich S, Jackson K, Reich K.
    J Clin Pharmacol; 2018 Nov 01; 58(11):1489-1500. PubMed ID: 29878382
    [Abstract] [Full Text] [Related]

  • 17. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C.
    J Eur Acad Dermatol Venereol; 2017 Jul 01; 31(7):1196-1207. PubMed ID: 28370467
    [Abstract] [Full Text] [Related]

  • 18. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
    Leonardi C, Maari C, Philipp S, Goldblum O, Zhang L, Burkhardt N, Ball S, Mallbris L, Gonzalez P, Fernández-Peñas P, Puig L.
    J Am Acad Dermatol; 2018 Nov 01; 79(5):824-830.e2. PubMed ID: 29803904
    [Abstract] [Full Text] [Related]

  • 19. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
    Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C.
    Acta Derm Venereol; 2019 Oct 01; 99(11):971-977. PubMed ID: 31240322
    [Abstract] [Full Text] [Related]

  • 20. Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies.
    Gooderham MJ, Elewski B, Augustin M, Iversen L, Torii H, Burge R, See K, Gallo G, Eastman WJ, McKean-Matthews M, Foley P.
    J Drugs Dermatol; 2021 Apr 01; 20(4):394-401. PubMed ID: 33852247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.